NCT04948437

Brief Summary

Now, the investigators carried out a prospective study enrolling patients with thyroid cancer, who had received ablative thyroidectomy and /or radioactive iodine therapy for two more years. The investigators' study already enrolled seventy-three patients with thyroid cancer, and the investigators plan to enroll 30 new patients in this consecutive research study. All patients received total thyroidectomy under clinically surgical judgement in initial therapeutic option. The investigators also further found some difference between papillary thyroid cancer and follicular thyroid cancer, and the investigators will continue annually to closely monitor the change of U-Ex Tg and urinary exosomal galectin-3 between differently cellular types of thyroid cancers.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
103

participants targeted

Target at P50-P75 for all trials

Timeline
6mo left

Started Aug 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress91%
Aug 2021Oct 2026

First Submitted

Initial submission to the registry

June 24, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 2, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

August 19, 2021

Completed
4.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 8, 2026

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2026

Expected
Last Updated

April 13, 2026

Status Verified

April 1, 2026

Enrollment Period

4.6 years

First QC Date

June 24, 2021

Last Update Submit

April 7, 2026

Conditions

Thyroid CancerPapillary Thyroid CancerFollicular Thyroid Cancer

Keywords

ExosomeUrineBiological markerThyroglobulinGalactin-3

Outcome Measures

Primary Outcomes (15)

  • Change of serum thyroglobulin level

    Thyroid function test

    Within 36 months

  • Change of serum free T4 level

    Thyroid function test

    Within 36 months

  • Change of serum TSH level

    Thyroid function test

    Within 36 months

  • Change of anti-thyroglobulin level

    Thyroid function test

    Within 36 months

  • Urinary exosomal thyroglobulin detection

    Urinary exosomal biomarker

    Within 36 months

  • Urinary exosomal galectin-3 detection

    Urinary exosomal biomarker

    Within 36 months

  • Urinary exosomal calprotectin A9 detection

    Urinary exosomal biomarker

    Within 36 months

  • Urinary exosomal transketolase detection

    Urinary exosomal biomarker

    Within 36 months

  • Urinary exosomal keratin 19 detection

    Urinary exosomal biomarker

    Within 36 months

  • Urinary exosomal angiopoietin-1 detection

    Urinary exosomal biomarker

    Within 36 months

  • Urinary exosomal tissue inhibitor of metalloproteinase detection

    Urinary exosomal biomarker

    Within 36 months

  • Urinary exosomal keratin 8 detection

    Urinary exosomal biomarker

    Within 36 months

  • Urinary exosomal calprotectin A8 detection

    Urinary exosomal biomarker

    Within 36 months

  • Urinary exosomal annexin II detection

    Urinary exosomal biomarker

    Within 36 months

  • Urinary exosomal afamin detection

    Urinary exosomal biomarker

    Within 36 months

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The investigators carried out a prospective study enrolling patients with thyroid cancer, who had received ablative thyroidectomy and /or radioactive iodine therapy for two more years. The study already enrolled seventy-three patients with thyroid cancer, and the investigators plan to enroll 30 new patients in this consecutive research study. All patients received total thyroidectomy under clinically surgical judgement in initial therapeutic option. The investigators also further found some difference between papillary thyroid cancer and follicular thyroid cancer, and we will continue annually to closely monitor the change of U-Ex Tg and urinary exosomal galectin-3 between differently cellular types of thyroid cancers.

You may qualify if:

  • diagnosed patients with thyroid papillary, follicular and anaplastic thyroid cancer, post-operation follow up

You may not qualify if:

  • unclearly diagnosed patients with thyroid papillary, follicular and anaplastic thyroid cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chih-Yuan Wang, M.D

Taipei, Taiwan

Location

MeSH Terms

Conditions

Thyroid NeoplasmsThyroid Cancer, PapillaryAdenocarcinoma, Follicular

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsEndocrine System DiseasesThyroid DiseasesAdenocarcinoma, PapillaryAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Study Officials

  • CHIH-YUAN WANG, Doctor

    Department of Internal Medicine, National Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 24, 2021

First Posted

July 2, 2021

Study Start

August 19, 2021

Primary Completion

April 8, 2026

Study Completion (Estimated)

October 31, 2026

Last Updated

April 13, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations

TW(1)